Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
News from the UK Stock Exchange

Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Osmotica Pharmaceutical Plc - news published 36 - readings 671

BACK

Osmotica Pharmaceutical plc

Statement of Changes in Beneficial Ownership (Form 4)

Ownership Submission FORM 4 Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investmen ...

26.01.2022

Osmotica Pharmaceutical plc

Statement of Changes in Beneficial Ownership (Form 4)

26.01.2022

Osmotica Pharmaceutical plc

Statement of Changes in Beneficial Ownership (Form 4)

26.01.2022

Osmotica Pharmaceutical plc

Statement of Changes in Beneficial Ownership (Form 4)

26.01.2022

Osmotica Pharmaceutical plc

Corporate Presentation January 2022

RVL Pharmaceuticals plc Corporate Presentation January 2022 1 Forward Looking Statements The financial and operating data included in this presentation for the fiscal year ended December 31, 2021 and for the fourth quarter of 2021 is preliminary and may change. This preliminary data has been prepared by, and is the responsibility of our management and no independent accounting ...

20.01.2022

Osmotica Pharmaceutical plc

Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance - Form 8-K

Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol "RVLP," Plans to Launch UPNEEQ ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance -- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarte ...

19.01.2022

Osmotica Pharmaceutical plc

Amendments to Articles of Incorporation/Bylaws/Change in Fiscal Year - Form 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2022 RVL Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland 001-38709 Not Applicable (State or other jurisdiction of i ...

18.01.2022

Osmotica Pharmaceutical plc

Statement of Changes in Beneficial Ownership (Form 4)

20.12.2021

Osmotica Pharmaceutical plc

Corporate Presentation December 2021

Osmotica Pharmaceuticals plc Corporate Presentation December 2021 1 Forward Looking Statements This presentation contains forward‐looking statements. You should not rely upon forward‐looking statements as predictions of future events. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "p ...

14.12.2021

Osmotica Pharmaceutical plc

Osmotica Pharmaceuticals plc Corporate Presentation December 2021

14.12.2021

Osmotica Pharmaceutical plc

Notice of Effectiveness (Form EFFECT)

Notice of Effectiveness UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Notice of Effectiveness Effectiveness Date: December 9, 2021 4:00 P.M. Form: S-3 CIK: 0001739426 Company Name: Osmotica Pharmaceuticals plc File Number: 333-260529 Attachments Original Link Original Document Permalink Disclaimer Osmotica Pharmaceutical plc published this content on ...

10.12.2021

Osmotica Pharmaceutical plc

Proxy Statement (Form DEF 14A)

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissio ...

08.12.2021

Osmotica Pharmaceutical plc

Regulation FD Disclosure - Form 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2021 Osmotica Pharmaceuticals plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-3 ...

17.11.2021

Osmotica Pharmaceutical plc

Initial Registration Statement for Employee Benefit Plan (Form S-8)

As filed with the Securities and Exchange Commission on November 16, 2021 REGISTRATION NO. 333 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT under the SECURITIES ACT OF 1933 Osmotica Pharmaceuticals plc (Exact Name of Registrant as Specified in Its Charter) Ireland Not Applicable ( State or Other Jurisdiction of Incor ...

16.11.2021

Osmotica Pharmaceutical plc

Quarterly Report (Form 10-Q)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the t ...

15.11.2021

Osmotica Pharmaceutical Plc - news published 36 - readings 671

Osmotica Pharmaceutical plc

Statement of Changes in Beneficial Ownership (Form 4)

Osmotica Pharmaceutical plc

Statement of Changes in Beneficial Ownership (Form 4)

Osmotica Pharmaceutical plc

Statement of Changes in Beneficial Ownership (Form 4)

Osmotica Pharmaceutical plc

Statement of Changes in Beneficial Ownership (Form 4)

Osmotica Pharmaceutical plc

Corporate Presentation January 2022

Osmotica Pharmaceutical plc

Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance - Form 8-K

Osmotica Pharmaceutical plc

Amendments to Articles of Incorporation/Bylaws/Change in Fiscal Year - Form 8-K

Osmotica Pharmaceutical plc

Statement of Changes in Beneficial Ownership (Form 4)

Osmotica Pharmaceutical plc

Corporate Presentation December 2021

Osmotica Pharmaceutical plc

Osmotica Pharmaceuticals plc Corporate Presentation December 2021

Osmotica Pharmaceutical plc

Notice of Effectiveness (Form EFFECT)

Osmotica Pharmaceutical plc

Proxy Statement (Form DEF 14A)

Osmotica Pharmaceutical plc

Regulation FD Disclosure - Form 8-K

Osmotica Pharmaceutical plc

Initial Registration Statement for Employee Benefit Plan (Form S-8)

Osmotica Pharmaceutical plc

Quarterly Report (Form 10-Q)

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member